Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:43:12.750Z.
Calculation as of: 2026-10-06T16:43:12.750Z.
Quote observation: 2026-10-06T16:40:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fc2e94c8beea8e322b310e9b25a1b89028fd55b2fc6a2790cf1d230843e32158
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$38.61M
EBITDA Yield
9.49%
TTM Avg
10.40%
3Y Avg
3.98%
5Y Avg
3.32%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incannex Healthcare Limited (IXHL) | $37.75M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.67M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.76M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.61M | 9.49% | 10.40% | 3.98% | 3.32% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.61M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A | 15.63% | 9.19% | 7.93% |
| Nephros, Inc. (NEPH)vs › | $39.84M | 4.90% | 3.36% | 3.05% | 3.05% |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.94M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.25M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.35M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
